Attributes | Values |
---|
rdf:type
| |
Description
| - In vivo depletion of CD8+ cells resulted in complete elimination of protective effects after immunization with TC-1 cells (MHC class I+) against the TC-1 tumour challenge. After immunization with TC-1/A9 or MK16 tumour cells (MHC class I-deficient) a remarkable dependence on the presence of NK1.1+ cells was observed, Cytotoxic activity induced by TC-1 cell immunization was abrogated in CD8+ cell-depleted mice and the mice showed similar percentage of IFNgamma-producing cells in CD8+, CD4+ and NK1.1+ subpopulations.. After MK16 or TC-1/A9 cell immunization, NK1.1+ displayed significant reduction of cytotoxicity. The highest proportion of IFNgamma-producing cells was concentrated into the NK1.1+ cells..
- In vivo depletion of CD8+ cells resulted in complete elimination of protective effects after immunization with TC-1 cells (MHC class I+) against the TC-1 tumour challenge. After immunization with TC-1/A9 or MK16 tumour cells (MHC class I-deficient) a remarkable dependence on the presence of NK1.1+ cells was observed, Cytotoxic activity induced by TC-1 cell immunization was abrogated in CD8+ cell-depleted mice and the mice showed similar percentage of IFNgamma-producing cells in CD8+, CD4+ and NK1.1+ subpopulations.. After MK16 or TC-1/A9 cell immunization, NK1.1+ displayed significant reduction of cytotoxicity. The highest proportion of IFNgamma-producing cells was concentrated into the NK1.1+ cells.. (en)
|
Title
| - NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
- NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours (en)
|
skos:prefLabel
| - NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
- NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours (en)
|
skos:notation
| - RIV/68378050:_____/11:00355110!RIV11-AV0-68378050
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(IAA500520807), Z(AV0Z50520514)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/11:00355110
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - MHC class I-deficient tumours; CD8+, CD4+, NK1.1+cell subpopulations; interferon gamma (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Reiniš, Milan
- Bieblová, Jana
- Bubeník, Jan
- Indrová, Marie
- Šímová, Jana
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
is http://linked.open...avai/riv/vysledek
of | |